Michael Sawyer, MD, associate professor, Medical Oncology, University of Alberta, discusses lean body mass (LBM) outcomes in patients with multicentric Castleman’s disease who received siltuximab (Sylvant).

Interleukin-6 (IL-6) plays a pivotal role in both multicentric Castleman’s disease and cachexia (loss of weight, muscle atrophy, fatigue, weakness). In this study, the mean maximal gain in LBM in the siltuximab-treated patients was 2.4 kg compared with 1.1 kg in those receiving placebo.

Further, Sawyer says, greater than 50% of patients treated with siltuximab gained more than 1 kg of LBM at first CT exam at 9 weeks. At no point did patients receiving placebo reach that level.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Hematologic Oncology

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Michael Sawyer, MD, associate professor, Medical Oncology, University of Alberta, discusses lean body mass (LBM) outcomes in patients with multicentric Castleman's disease who received siltuximab (Sylvant).


Dr. Sawyer on LBM Outcomes With Siltuximab in Multicentric Castleman's Disease